The goal of blood pressure control for prevention of early diabetic microvascular complications

Current Diabetes Reports

Volumn 11, Issue 4, 2011, Pages 323-329

  Williams, Mark E ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

Blood pressure control; Diabetes mellitus; Hypertension; Microvascular complications; Primary prevention

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; PLACEBO; TRANDOLAPRIL; VERAPAMIL;

AGE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY PREVENTION; REVIEW; RISK FACTOR;

ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES COMPLICATIONS; HUMANS; HYPERTENSION;

EID: 80051592268     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-011-0193-z     Document Type: Review

References (54)

1. World Health Organization: Diabetes fact sheet N°312. Available at http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed April 6, 2011.
2. ML Gross R Dikow E Ritz 2005 Diabetic nephropathy: recent insights into the pathophysioology and the progression of diabetic nephropathy Kidney Int 67 Suppl 94 S50 S53 10.1111/j.1523-1755.2005.09412.x (Pubitemid 44324770)
3. JR Sowers M Epstein ED Frohlich 2001 Diabetes, hypertension, and cardiovascular disease: an update Hypertension 37 1053 59 11304502 1:CAS:528:DC%2BD3MXjtFejt7g%3D (Pubitemid 32304003)
4. GL Bakris M Williams L Dworkin, et al. 2000 Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Am J Kidney Dis 36 646 661 10977801 10.1053/ajkd.2000.16225 1:STN:280: DC%2BD3cvjsFSqsw%3D%3D
5. J Karalliedde G Viberti 2010 Proteinuria in diabetes: bystander or pathway to cardiorenal disease? J Am Soc Nephrol 21 2020 2027 21051738 10.1681/ASN.2010030250 1:CAS:528:DC%2BC3MXktVer
6. L Gnudi SM Thomas G Viberti 2007 Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism J Am Soc Nephrol 1 2226 2232 10.1681/ASN.2006121362 (Pubitemid 47203836)
7. M Haneda R Kikkawa M Togawa, et al. 1992 High blood pressure is a risk factor for the development of microalbuminuria in Japanese subjects with non-insulin-dependent diabetes mellitus J Diabetes Complications 6 181 185 1472744 10.1016/1056-8727(92)90034-I 1:STN:280:DyaK3s7htlSntw%3D%3D (Pubitemid 23129151)
8. P Ruggenenti A Perna M Ganeva, et al. 2006 BENEDICT study group: Impact of blood pressure and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post-hoc analysis of the BENEDICT trial J Am Soc Nephrol 17 3472 3481 17082240 10.1681/ASN.2006060560 1:CAS:528:DC%2BD28XhtlGiu7bK (Pubitemid 44865289)
9. JB Lewis T Berl RP Bain, et al. 1999 Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy Am J Kidney Dis 34 809 817 10561135 10.1016/S0272-6386(99)70036-3 1:STN:280:DC%2BD3c%2FjtVWqsw%3D%3D (Pubitemid 29521695)
10. MA Pohl S Blumenthal DJ Cordonnier, et al. 2005 Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations J Am Soc Nephrol 16 3027 3037 16120823 10.1681/ASN.2004110919 1:CAS:528:DC%2BD2MXhtFegtLnE (Pubitemid 44743500)
11. P Rossing HH Parving D de Zeeuw 2006 Renoprotection by blocking the RAAS in diabetic nephropathy-fact or fiction? Nephrol Dial Transplant 21 2354 2357 16928724 10.1093/ndt/gfl454 (Pubitemid 44644501)
12. P Ruggenenti P Cravedi G Remuzzi 2010 The RAAS in the pathogenesis and treatment of diabetic nephropathy Nature Rev/Nephr 6 319 330 10.1038/nphys1659 1:CAS:528:DC%2BC3cXmsFymtb4%3D This is a scholarly report documenting the importance of the renin-angiotensin-aldosterone system pathway in diabetic kidney disease; review includes major clinical trials for prevention of microalbuminuria.
13. BK Srivastava M Rema 2005 Does hypertension play a role in diabetic retinopathy? JAPI 53 803 808 16334627 1:STN:280:DC%2BD2MnltlOhsQ%3D%3D (Pubitemid 41365565)
14. UK Prospective Diabetes Study Group 1998 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes BMJ 317 703 713
15. J McGill 2009 Improving microvascular outcomes in patients with diabetes through management of hypertension Postgrad Med 121 89 101 19332966 10.3810/pgm.2009.03.1980
16. K Norgaard B Feldt-Rasmussen K Johnsen, et al. 1990 Prevalence of hypertension in type 1 (insulin dependent) diabetes mellitus Diabetologia 33 407 410 2401396 10.1007/BF00404089 1:STN:280:DyaK3czot1KmtA%3D%3D (Pubitemid 20220939)
17. H-H Parving E Hommel E Mathiesen, et al. 1988 Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin-dependent diabetes Br Med J 296 156 160 10.1136/bmj.296.6616.156 1:STN:280:DyaL1c7gvVOiuw%3D%3D
18. CE Mogensen 1984 Predicting diabetic nephropathy in insulin-dependent patients New Eng J Med 311 89 93 6738599 10.1056/NEJM198407123110204 1:STN:280:DyaL2c3ksFKlsA%3D%3D (Pubitemid 14084080)
19. M Bohm M Thoenes N Danchin, et al. 2007 Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study J Hypertension 25 2317 2324 10.1097/HJH.0b013e3282ef1c5f (Pubitemid 47537927)
20. H Haller GC Viberti A Mimran, et al. 2006 Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study J Hypertension 24 403 408 10.1097/01.hjh.0000202820.56201.e6 1:CAS:528:DC%2BD28XhslamurY%3D (Pubitemid 43348255)
21. E Lurge J Redon A Kesani, et al. 2002 Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes N Engl J Med 347 797 805 10.1056/NEJMoa013410 (Pubitemid 34988338)
22. Brenner BM (Ed.) Brenner and Rector's The Kidney (W.B.Saunders, Philadelphia, 2008).
23. HC Gerstein JFE Mann Q Yi, et al. 2001 Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals JAMA 286 421 426 11466120 10.1001/jama.286.4.421 1:CAS:528:DC%2BD3MXlvFKksL0%3D (Pubitemid 32681484)
24. M-A Gall P Hougaard K Borch-Johnsen, et al. 1997 Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study Brit Med J 314 783 788 9080995 1:STN:280:DyaK2s3js1SrsQ%3D%3D (Pubitemid 27117048)
25. Y Vergouwe SS Soedamah-Muthu J Zgibor, et al. 2009 Progression to microalbuminuria in type 1 diabetes: Development and validation of a prediction rule Diabetologia 53 254 262 19908023 10.1007/s00125-009-1585-3
26. B Najafian M Mauer 2009 Progression of diabetic nephropathy in type 1 diabetic patients Diabetes Research Clinical Practice 83 1 8 10.1016/j.diabres.2008.08.024 1:CAS:528:DC%2BD1cXhsFChurnI
27. BA Perkins LH Ficociello BE Ostrander, et al. 2007 Microalbuminuria and the risk for early progressive function decline in type 1 diabeters J Am Soc Nephrol 18 1353 1361 17329575 10.1681/ASN.2006080872 1:CAS:528: DC%2BD2sXkslSrtrw%3D (Pubitemid 46536923)
28. Murussi M, Gross JL, Silviero SP. Glomerular filtration rate changes in normoalbuminuric and microalbuminuric type 2 diabetic patients and normal individuals.
29. VS Vaidya MA Niewczas LH Ficociello, et al. 2011 Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-B-D- glucosaminidasse Kidney Int 79 464 470 20980978 10.1038/ki.2010.404 1:CAS:528:DC%2BC3MXht1ylsrw%3D
30. MG Atta K Baptiste-Roberts FL Brancati, et al. 2009 The natural course of microalbuminuria among African Americans with type 2 diabetes: a 3-year study Am J Med 122 62 72 19114173 10.1016/j.amjmed.2008.07.023 1:CAS:528: DC%2BD1cXhsFCgsrfP
31. AW Patrick PJ Leslie BF Clarke, et al. 1990 The natural history and associations of microalbuminuria in type 2 diabetes during the first year after diagnosis Diabet Med 7 902 908 2149687 10.1111/j.1464-5491.1990.tb01326.x 1:STN:280:DyaK3M7ks1amsw%3D%3D
32. LH Ficociello BA Perkins B Roshan, et al. 2009 Renal hyperfiltration and the development of microalbuminuria in type 1 diabetes Diabetes Care 32 889 893 19196883 10.2337/dc08-1560 1:CAS:528:DC%2BD1MXmt1Wnur0%3D
33. PL Poulsen KW Hansen CE Mogensen 1994 Ambulatory blood pressure in the transition from normo- to microalbuminuria. A longitudinal study in IDDM patients Diabetes 43 1248 53 7926296 10.2337/diabetes.43.10.1248 1:STN:280:DyaK2M%2FhtFSlsA%3D%3D (Pubitemid 24361192)
34. Ito H, Takeuchi Y, Ishida H, et al. High frequencies of diabetic micro- and macroangiopathies with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria. Nephr Dial Transplant November 5, 2009 (epub ahead of print)
35. TH Hostetter JL Troy BM Brenner 1981 Glomerular hemodynamics in experimental diabetes mellitus Kidney Int 19 410 415 7241881 10.1038/ki.1981.33 1:CAS:528:DyaL3MXhslagsLg%3D (Pubitemid 11112621)
36. G Wolf F Ziyadeh 2007 Cellular and molecular mechanisms of proteinuria in diabetic nephropathy Nephron Physiol 106 26 31 10.1159/000101797 (Pubitemid 46920097)
37. KC Silva CC Pinto SK Biswas, et al. 2007 Hypertension increases retinal inflammation in experimental diabetes: a possible mechanism for aggravation of diabetic retinopathy by hypertension Curr Eye Res 32 533 541 17612969 10.1080/02713680701435391 1:CAS:528:DC%2BD2sXnt1Whur8%3D (Pubitemid 47039108)
38. PN Van Buren R Toto 2011 Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management Adv Chr Kidney Dis 18 28 41 10.1053/j.ackd.2010.10.003 This is a thorough review of hypertension in diabetes, including epidemiology, mechanisms, and management, with a review of recent clinical trials that form the basis of clinical treatment guidelines.
39. RG Nelson KR Tuttle 2010 Prevention of diabetic kidney disease: negative clinical trials with renin-angiotensin system inhibitors Am J Kid Disease 55 426 430 10.1053/j.ajkd.2009.10.001
40. AV Chobanian 2009 Shattuck lecture. The hypertension paradox-more uncontrolled disease despite improved therapy N Engl J Med. 361 878 887 19710486 10.1056/NEJMsa0903829 1:CAS:528:DC%2BD1MXhtVKhtL3I
41. A Chobanian GL Bakris HR Black, et al. 2003 The seventh joint national committee report on prevention, detection, and treatment of high blood pressure JAMA 289 2560 2572 12748199 10.1001/jama.289.19.2560 1:CAS:528: DC%2BD3sXjvFCqtrk%3D (Pubitemid 37430158)
42. ACCORD Study Group 2010 Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 1575 1585 10.1056/NEJMoa1001286
43. R Kalaitzidis GL Bakris 2009 Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible? J Clin Hypertens 11 345 347 10.1111/j.1751-7176.2009.00143.x
44. American Diabetes Association 2009 Clinical practice recommendations 2009 Diabetes Care 32 Suppl 1 S1 S98
45. BA Perkins LP Aiello AS Krolewskik 2009 Diabetes complications and the renin-angiotensin system New Engl J Med 361 83 85 19571288 10.1056/NEJMe0904293 1:CAS:528:DC%2BD1MXotV2gt7s%3D
46. Euclid Study Group 1997 Randomised placebo-controlled trial of lisinopril in mormotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria Lancet 349 1787 92 10.1016/S0140-6736(96)10244-0 (Pubitemid 27257554)
47. P Ruggenenti A Fassi AP Ilieva, et al. 2004 Preventing microalbumiuria in type 2 diabetes New Eng J Med 351 1941 1951 15516697 10.1056/NEJMoa042167 1:CAS:528:DC%2BD2cXps1Wlt70%3D (Pubitemid 39447135)
48. P Ruggenenti A Perna M Ganeva, et al. 2006 BENEDICT Study Group: Impact of blood pressure and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post-hoc analysis of the BENEDICT trial J Am Soc Nephrol 17 3472 3481 17082240 10.1681/ASN.2006060560 1:CAS:528:DC%2BD28XhtlGiu7bK (Pubitemid 44865289)
49. M Mauer B Zinman R Gardiner, et al. 2009 Renal and retinal effects of enalapril and losartan in type 1 diabetes N Engl J Med 361 40 51 19571282 10.1056/NEJMoa0808400 1:CAS:528:DC%2BD1MXotV2hu70%3D
50. Strippoli GF, Craig M, Navaneethan SD, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006; CD0006257
51. R Bilous N Chaturvedi AK Sjolie, et al. 2009 Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials Ann Intern Med 151 11 20 19451554
52. H Haller S Ito JR Izzo Jr, et al. 2011 Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes N Eng J Med 364 907 917 10.1056/NEJMoa1007994 1:CAS:528:DC%2BC3MXjtFensLk%3D
53. AS Levey D Cattran A Friedman, et al. 2009 Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration Am J Kidney Dis 54 205 226 19577347 10.1053/j.ajkd.2009.04.029
54. KL Ong BMY Cheung YB Man, et al. 2007 Prevalence, awareness, treatment, and control of hypertension among United States adults, 1999-2004 Hypertension 49 69 75 17159087 10.1161/01.HYP.0000252676.46043.18 1:CAS:528: DC%2BD28XhtlSrs7vI (Pubitemid 46360343)